Reginster Jean-Yves, Bruyere Olivier, Lecart Marie-Paul, Henrotin Yves
Bone and Cartilage Metabolism Research Unit, University of Liège, Belgium.
Curr Opin Rheumatol. 2003 Sep;15(5):651-5. doi: 10.1097/00002281-200309000-00022.
Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis.
The most compelling evidence of a potential for inhibiting the structural progression of osteoarthritis has been obtained with glucosamine sulfate, whereas preliminary results obtained in patients with osteoarthritis of the hands also suggest that chondroitin sulfate could be used in the same indication. At any rate, these two compounds have clearly demonstrated a symptomatic action, mainly in osteoarthritis of the lower limbs. Patients with the less severe radiographic osteoarthritis will experience, in the long run, the most dramatic disease progression in terms of joint space narrowing. Such patients may be particularly responsive to structure-modifying drugs.
Glucosamine sulfate has demonstrated its ability to reduce the progression of osteoarthritis in the lower limbs. The preliminary results obtained in the hands suggest that chondroitin sulfate could also be of interest in this indication. An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, not over-the-counter pills or food supplements.
为了对骨关节炎进行症状和结构管理，人们对多种物质进行了仔细研究。本综述报告了近期的研究结果，这些结果表明此类化合物可能会延缓骨关节炎的结构进展。
硫酸氨基葡萄糖已经获得了抑制骨关节炎结构进展潜力的最有力证据，而手部骨关节炎患者的初步结果也表明硫酸软骨素可用于相同适应症。无论如何，这两种化合物已明确显示出有症状缓解作用，主要针对下肢骨关节炎。从长期来看，影像学上骨关节炎不太严重的患者在关节间隙变窄方面会经历最显著的疾病进展。这类患者可能对结构改善药物特别敏感。
硫酸氨基葡萄糖已证明其能够减缓下肢骨关节炎的进展。手部的初步研究结果表明硫酸软骨素在这一适应症中也可能具有应用价值。一个重要问题是，所有关于此类化学物质的确定性研究均源于处方药的使用，而非非处方药或食品补充剂。
